Allelic loss and the progression of breast cancer.

To study genetic changes and the evolution of breast cancer, we assayed for loss of heterozygosity (LOH) in 12 sets of synchronous carcinoma in situ (CIS) and invasive cancer, compared to normal control DNA. Microsatellite markers were used, which map to each nonacrocentric autosomal arm. Eight tumor sets demonstrated LOH of the same allele in both concurrent invasive cancer and ductal CIS, for a total of 18 chromosomal loci. Three of nine tumor sets showed LOH on 11p. In two of these sets, LOH was seen on 11p only in the invasive tumor, not the corresponding CIS. One of these tumors also exhibited allelic loss in the invasive tumor for 4 loci, all of which were retained in the noninvasive tumor. For two tumor sets, LOH was mirrored in matched ductal CIS, invasive tumor, and lymph node metastasis. The maintenance of LOH for certain loci throughout the stages of breast cancer suggests clonality of the cancer cells.

[1]  N. Phillips,et al.  Allelotyping of ductal carcinoma in situ of the breast: deletion of loci on 8p, 13q, 16q, 17p and 17q. , 1995, Cancer research.

[2]  L. Liotta,et al.  Identical allelic loss on chromosome 11q13 in microdissected in situ and invasive human breast cancer. , 1995, Cancer research.

[3]  A. Thompson,et al.  Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. , 1993, Cancer research.

[4]  P. Watson,et al.  Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. , 1993, Journal of the National Cancer Institute.

[5]  Y. Nakamura,et al.  Correlation of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes. , 1992, Cancer research.

[6]  Peter A. Jones,et al.  Progressing toward a molecular description of colorectal cancer development , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[7]  M. Greene,et al.  Expression of c-erbB-2 in in situ and in adjacent invasive ductal adenocarcinomas of the female breast. , 1992, Pathobiology : journal of immunopathology, molecular and cellular biology.

[8]  Å. Borg,et al.  Chromosome 1 alterations in breast cancer: allelic loss on 1p and 1q is related to lymphogenic metastases and poor prognosis. , 1992, Genes, chromosomes & cancer.

[9]  D. Schultz,et al.  Ten‐year results of breast‐conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ) of the breast , 1991, Cancer.

[10]  P L Pearson,et al.  Allelotype of human breast carcinoma: a second major site for loss of heterozygosity is on chromosome 6q. , 1991, Oncogene.

[11]  J. Marks,et al.  Maintenance of p53 alterations throughout breast cancer progression. , 1991, Cancer research.

[12]  J. Marks,et al.  Maintenance of p 53 Alterations throughout Breast Cancer Progression 1 , 1991 .

[13]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[14]  C. M. Steel,et al.  Partial deletion of chromosome 11p in breast cancer correlates with size of primary tumour and oestrogen receptor level. , 1988, British Journal of Cancer.

[15]  David L. Page,et al.  Diagnostic Histopathology of the Breast , 1988 .

[16]  C. Alpers,et al.  The prevalence of carcinoma in situ in normal and cancer-associated breasts. , 1985, Human pathology.

[17]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[18]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.